|
Mar 20
|
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
|
|
Mar 20
|
UPDATE 3-Lonza to buy large biologics site from Roche in US for $1.2 bln
|
|
Mar 20
|
Lonza to buy large biologics site from Roche in US for $1.2 billion
|
|
Feb 4
|
Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.60
|
|
Feb 1
|
Health Care Roundup: Market Talk
|
|
Feb 1
|
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
|
|
Feb 1
|
Roche shuffles early stage pipeline as it joins obesity rush
|
|
Feb 1
|
Roche Expects Sales, Core Earnings Growth
|
|
Feb 1
|
Roche shares fall on modest 2024 outlook
|
|
Feb 1
|
UPDATE 4-Roche sees pick up in growth as it overcomes drop in COVID sales
|
|
Feb 1
|
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
|
|
Feb 1
|
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
|
|
Feb 1
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
|
|
Jan 16
|
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
|
|
Jan 16
|
Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU
|
|
Jan 16
|
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
|
|
Jan 12
|
The Zacks Analyst Blog Highlights Roche, Netflix, NIKE, Uber, Technologies and Prologis
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|
|
Jan 11
|
Top Research Reports for Roche, Netflix & NIKE
|
|
Jan 11
|
Renewables grew rapidly in 2023, but must grow faster still to meet climate change target, IEA says
|